Suzhou Connect Reports Positive Data from Autoimmune Drug Trial

Suzhou Connect Biopharma reported positive data from a Phase Ib trial of its lead clinical candidate, CBP-307, a novel immune system modulator that Connect is developing as a treatment for autoimmune diseases. The double-blind study showed the drug was well-tolerated and produced a significant reduction in immune activity. CBP-307 is a second generation selective sphingosine-1-phosphate receptor 1 (S1P1) modulator. Connect expects it will show improved safety over first generation S1P1 drugs. More details.... Share this with colleagues: // //